Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.

Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.

Recent News
Apr 18, 2024

—Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the...

Apr 2, 2024

—“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving...

Mar 25, 2024

—European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis— —Further Extends Protections Afforded...

Mar 7, 2024

─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025─ ─Cash Runway Extended...

All News

Stock Info
Wednesday, April 10, 2024
10:00am EDT

Listen to the Replay

Format: Virtual webcast with live Q&A
SpeakersChristopher Bowlus MD, Chief, Division of Gastroenterology & Hepatology, UC Davis Health
Massimo Pinzani, MD, PhD, UCL Professor of Medicine, Founder of the UCL Institute for Liver and Digestive Health & Science Director, ISMETT UPMC
Ricky Safer, Founder & CEO, PSC Partners Seeking a Cure

Tuesday, March 12, 2024
10:40am EDT

Date: Mar. 12, 2024
Time: 10:40 am ET
Venue: Fontainebleau Hotel
Format: Live presentation
Information: LeerinkEvents@Leerink.com

All Events

Featured Presentations


Chemomab Corporate Overview - April 2024


Annual Report


Chemomab 2022 Annual Report